Call 888-776-0942 from 8 a.m. to 10 p.m. Eastern Time

Hamamatsu, Japan, December 14, 2021 /PRNewswire/ - Hamamatsu Photonics KK, a leading supplier of full-slide imaging systems, is collaborating with Techcyte, a leading clinicopathology AI platform provider, to advance the clinic by improving the entire slide Imaging of pathological non-histological samples.

Digital pathology is usually related to anatomical pathology and histology. However, the ability to scan non-histological samples will help mid-to-high-throughput laboratories maximize the effectiveness of the entire slide scanner. In addition, advances in artificial intelligence (AI) are improving the accuracy and efficiency of anatomical and clinical pathology tests.

Unlike histological slides, slides prepared with liquids and smears can be very difficult to digitize because they can be sparse and uneven. To overcome these obstacles and expand scanning capabilities, Techcyte uses Hamamatsu's API (application programming interface) to improve the scanning of human and veterinary stool samples, blood smears, Pap smears, bacteriological samples, and airborne mold. The Hamamatsu API enables Techcyte to use artificial intelligence and computer vision technology to pre-scan and locate the best scanning area to improve focus. This new method improves the quality of the generated images and reduces the file size, further shortening the upload and analysis time.

The collaboration between Hamamatsu and Techcyte will first be used in the laboratory to digitize and identify human fecal eggs and parasites, cervical cytology and mold samples, and other sample types and tests will be followed up quickly. Ben Cahoon, CEO of Techcyte, said: “Excellent AI algorithms and workflow depend on excellent images, so working with Hamamatsu to improve the entire slide imaging is critical to our success. Hamamatsu is willing to share their scanner API for these two Each industry has set an example to work together to improve human health."

Scott Blakely, Business Development Manager at Hamamatsu, said: "This collaboration will increase opportunities. Our high-volume scanners can be used to benefit the laboratory, ultimately benefiting patients, and obtain faster and more accurate results."

For more information on how Hamamatsu and Techcyte can help digitize and improve clinical pathology, please visit our website www.nanozoomer.com and www.techcyte.com.

Hamamatsu Photonics KK Hamamatsu Photonics KK is a leading manufacturer of photonic devices. We design, manufacture and sell optical sensors, light sources, optical components, cameras, photometric systems, and measurement/analysis systems.

Techcyte Techcyte, Inc. was established in 2013 and has offices in Orem, Utah and Luxembourg. Its mission is to achieve digitalization and automated diagnosis. Techcyte's clinical pathology AI platform is revolutionizing human, veterinary, and environmental diagnostic testing. This platform enables clinics and laboratories to digitize their diagnostic workflows to improve the accuracy and efficiency of their tests.

Cision Distribution 888-776-0942 8 a.m. to 9 p.m. Eastern Time